Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

BACKGROUND Screening for prostate cancer advances the time of diagnosis (lead time) and detects cancers that would not have been diagnosed in the absence of screening (overdetection). Both consequences have considerable impact on the net benefits of screening. METHODS We developed simulation models based on results of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC), which enrolled 42,376 men and in which 1498 cases of prostate cancer were identified, and on baseline prostate cancer incidence and stage distribution data. The models were used to predict mean lead times, overdetection rates, and ranges (corresponding to approximate 95% confidence intervals) associated with different screening programs. RESULTS Mean lead times and rates of overdetection depended on a man's age at screening. For a single screening test at age 55, the estimated mean lead time was 12.3 years (range = 11.6-14.1 years) and the overdetection rate was 27% (range = 24%-37%); at age 75, the estimates were 6.0 years (range = 5.8-6.3 years) and 56% (range = 53%-61%), respectively. For a screening program with a 4-year screening interval from age 55 to 67, the estimated mean lead time was 11.2 years (range = 10.8-12.1 years), and the overdetection rate was 48% (range = 44%-55%). This screening program raised the lifetime risk of a prostate cancer diagnosis from 6.4% to 10.6%, a relative increase of 65% (range = 56%-87%). In annual screening from age 55 to 67, the estimated overdetection rate was 50% (range = 46%-57%) and the lifetime prostate cancer risk was increased by 80% (range = 69%-116%). Extending annual or quadrennial screening to the age of 75 would result in at least two cases of overdetection for every clinically relevant cancer detected. CONCLUSIONS These model-based lead-time estimates support a prostate cancer screening interval of more than 1 year.

[1]  D. Gunnell,et al.  International trends in prostate‐cancer mortality in the “PSA era” , 2001, International journal of cancer.

[2]  H. Carter,et al.  Mixed-effects regression models for studying the natural history of prostate disease. , 1994, Statistics in medicine.

[3]  J. Coebergh,et al.  Incidence of cancer in the Netherlands. , 2001 .

[4]  S. Ciatto,et al.  Overdiagnosis of prostate carcinoma by screening: an estimate based on the results of the Florence Screening Pilot Study. , 1998, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  G Bartsch,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001, Urology.

[6]  P. Jongbloet.  Incidence of cancer , 2001, The Lancet.

[7]  H. D. de Koning,et al.  Effective PSA contamination in the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer , 2003, International journal of cancer.

[8]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part II: Cause of death misclassification and the recent rise and fall in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.

[9]  J. Gohagan,et al.  The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. , 2000, Controlled clinical trials.

[10]  H. D. de Koning,et al.  Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial , 2002, International journal of cancer.

[11]  J D Habbema,et al.  The MISCAN simulation program for the evaluation of screening for disease. , 1985, Computer methods and programs in biomedicine.

[12]  J. Habbema,et al.  Changing role of 3 screening modalities in the European randomized study of screening for prostate cancer (Rotterdam) , 1999, International journal of cancer.

[13]  J A Hanley,et al.  Screening for prostate cancer: estimating the magnitude of overdetection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[14]  M. Stampfer,et al.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. , 1995, JAMA.

[15]  C. Newschaffer,et al.  Causes of death in elderly prostate cancer patients and in a comparison nonprostate cancer cohort. , 2000, Journal of the National Cancer Institute.

[16]  Harry J de Koning,et al.  Large‐scale randomized prostate cancer screening trials: Program performances in the European randomized screening for prostate cancer trial and the prostate, lung, colorectal and ovary cancer trial , 2002, International journal of cancer.

[17]  P. Knekt,et al.  Serum concentrations of prostate specific antigen and its complex with α1-antichymotrypsin before diagnosis of prostate cancer , 1994, The Lancet.

[18]  R BartonRussell,et al.  Nelder-Mead Simplex Modifications for Simulation Optimization , 1996 .

[19]  W. Kirkels,et al.  Trends in the curative treatment of localized prostate cancer after the introduction of prostate‐specific antigen: data from the Rotterdam Cancer Registry , 2000, BJU international.

[20]  Z. Hall.  Cancer , 1906, The Hospital.

[21]  Rob Boer,et al.  The MISCAN-COLON Simulation Model for the Evaluation of Colorectal Cancer Screening , 1999, Comput. Biomed. Res..

[22]  J. Coebergh,et al.  Incidence of Cancer in the Netherlands 1998 , 2002 .

[23]  László Tabár,et al.  Quantitative Interpretation of Age-Specific Mortality Reductions From the Swedish Breast Cancer-Screening Trials , 1995 .

[24]  E. Feuer,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality. , 1999, Journal of the National Cancer Institute.

[25]  B. Achinstein,et al.  Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance. , 2009, Nutrition reviews.

[26]  H. D. de Koning,et al.  Health-related quality-of-life effects of radical prostatectomy and primary radiotherapy for screen-detected or clinically diagnosed localized prostate cancer. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  W. Catalona,et al.  Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. , 1993, JAMA.

[28]  P. Prorok,et al.  Prospective Evaluation Plan for Randomised Trials of Prostate Cancer Screening , 1996, Journal of medical screening.

[29]  L. M. Franks.  Latent carcinoma of the prostate. , 1954, The Journal of pathology and bacteriology.

[30]  Mokhtar S. Bazaraa,et al.  Nonlinear Programming: Theory and Algorithms , 1993 .

[31]  J. S. Ivey,et al.  Nelder-Mead simplex modifications for simulation optimization , 1996 .

[32]  Mesut Remzi,et al.  Pathological features of prostate cancer detected on initial and repeat prostate biopsy: Results of the prospective European prostate cancer detection study , 2001, The Prostate.

[33]  S. Piantadosi,et al.  Clinical evidence for and implications of the multistep development of prostate cancer. , 1990, The Journal of urology.

[34]  P. Walsh,et al.  Cancer surveillance series: interpreting trends in prostate cancer--part I: evidence of the effects of screening in recent prostate cancer incidence, mortality, and survival rates. , 2000, The Journal of urology.

[35]  P. Walsh,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2003, The Journal of urology.

[36]  H. D. de Koning,et al.  Quantitative interpretation of age-specific mortality reductions from the Swedish breast cancer-screening trials. , 1995, Journal of the National Cancer Institute.

[37]  G. Stemmermann,et al.  Comparative studies of prostate cancer in Japan versus the United States. A review. , 2000, Urologic oncology.

[38]  T. H. van der Kwast,et al.  Detection of prostate cancer: a comparative study of the diagnostic efficacy of sextant transrectal versus sextant transperineal biopsy. , 2000, Urology.

[39]  C C Schulman,et al.  Prospective evaluation of prostate cancer detected on biopsies 1, 2, 3 and 4: when should we stop? , 2001, The Journal of urology.

[40]  Peter Boyle,et al.  Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. , 2001 .

[41]  H. Carter,et al.  Natural history of changes in prostate specific antigen in early stage prostate cancer. , 1994, The Journal of urology.

[42]  F. Labrie,et al.  Evaluation of prostatic specific antigen and digital rectal examination as screening tests for prostate cancer , 2000, The Prostate.

[43]  J. Hugosson,et al.  Would prostate cancer detected by screening withprostate‐specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population‐based studies in Sweden , 2000, BJU international.